Streetbeat News

KRRO

Korro Bio, Inc.

https://www.korrobio.com

Industry

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Open

68.90

Mkt cap

656M

Volume

13K

High

70.59

P/E Ratio

-7.68

52-wk high

98.00

Low

68.01

Div yield

N/A

52-wk low

30.00

Korro Bio's stock is rising following a collaboration announcement with Novo Nordisk to develop genetic medicines targeting cardiometabolic diseases.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:26 pm

Korro Bio has announced a collaboration with Novo Nordisk to develop two therapeutic candidates using Korro's OPERA platform for RNA editing, targeting cardiometabolic diseases. The deal is valued at up to $530 million, including milestone payments, royalties, and R&D funding.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:12 pm

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) with an Outperform rating, highlighting its proprietary OPERA platform for RNA editing. The analyst also noted the upcoming clinical data release from Wave Life Sciences Ltd (NASDAQ:WVE) and mentioned Beam Therapeutics Inc (NASDAQ:BEAM) as a validating but differentiable competitor.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 6:21 pm

RBC Capital analyst Luca Issi maintains an Outperform rating on Korro Bio (NASDAQ:KRRO) but lowers the price target from $105 to $95.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:35 pm

Korro Bio shares are trading higher following Q2 financial results and an Outperform rating from William Blair.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:32 pm

William Blair initiates coverage on Korro Bio (NASDAQ:KRRO) with an Outperform rating, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:06 pm

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Korro Bio (NASDAQ:KRRO) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:01 pm

Korro Bio (NASDAQ:KRRO) reported a Q2 EPS of $(2.43), missing the analyst consensus estimate of $(2.40) by 1.25%. This represents a 96.19% improvement over the $(63.83) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:14 pm

Korro Bio has been added to the Russell 2000, Russell 3000, and Russell Microcap Indexes. This inclusion is expected to increase the stock's visibility and attract more institutional investors.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:06 pm

HC Wainwright & Co. has reiterated its Buy rating on Korro Bio (NASDAQ:KRRO) and maintained a $100 price target, as stated by analyst Mitchell Kapoor.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 10:36 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.